CBLI Key Stats
- CLEVELAND BIOLABS INC Financials May 17
- 4 Healthcare Stock Stories For Tuesday Investment Wellness May 14
- InPlay: Cleveland Biolabs and Incuron announce US and European patent allowances... May 14
- Cleveland BioLabs and Incuron Announce US and European Patent Allowances for Cur... May 14
- Cleveland BioLabs' CEO Discusses Q1 2013 Results - Earnings Call Transcript Seeking Alpha May 9
- CORRECTION -- Cleveland BioLabs Reports First Quarter 2013 Financial Results and... May 9
- Cleveland Biolabs, Inc. (CBLI) Posts Q1 Loss of 22c/Share Street Insider May 9
- Cleveland BioLabs Reports First Quarter 2013 Financial Results and Development P... May 9
- Q1 2013 CLEVELAND BIOLABS INC Earnings Release - Before Market Open May 9
- CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Co... May 9
CBLI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Cleveland BioLabs is up 22.35% over the last year vs S&P 500 Total Return up 31.59%, Athersys up 41.91%, and Osiris Therapeutics up 92.25%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for CBLI
Pro Report PDF for CBLI
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download CBLI Pro Report PDF
Pro Strategies Featuring CBLI
Did Cleveland BioLabs make it into our Pro Portfolio Strategies?